The U.S. Food and Drug Administration has declined to approve Summit Therapeutics’ Biologics License Application for ivonescimab, a novel lung cancer treatment, the company announced on November 15, 2026. The regulatory decision came in the form of a Complete Response Letter (CRL), with the agency concluding that clinical data submitted by the company failed to demonstrate a statistically significant overall survival benefit for patients.
The application sought approval for ivonescimab in combination with platinum-based chemotherapy to treat patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) mutations. The proposed indication targeted individuals whose disease had progressed after receiving prior treatment with an EGFR tyrosine kinase inhibitor (TKI).
According to Summit Therapeutics, the FDA stated in its letter that the drug application could not be approved in its current form because overall survival evidence did not satisfy regulatory thresholds. The agency concluded that demonstrating a benefit in progression-free survival alone—without a statistically significant improvement in overall survival—is insufficient to establish substantial evidence of effectiveness or support a favorable benefit-risk profile in this patient population.
HARMONi Trial Shows Progression-Free Benefit but Misses Survival Goal
The regulatory submission relied heavily on data from the Phase III HARMONi study, a global, randomized, double-blind clinical trial evaluating 438 patients. The trial was designed with two co-primary endpoints: progression-free survival, which measures how long patients live without their cancer worsening, and overall survival, which tracks total survival time regardless of disease progression.
In the trial, ivonescimab combined with chemotherapy achieved its progression-free survival goal, demonstrating a 48% reduction in the risk of disease progression or death compared to chemotherapy alone. However, the primary analysis of overall survival failed to reach statistical significance.
Summit reported that a subsequent post-hoc analysis utilizing a June 2026 data cutoff showed an overall survival hazard ratio of 0.76 with a nominal p-value of 0.0151. Despite these additional findings, the FDA maintained its determination that the primary survival endpoint failure precluded regulatory approval at this stage.
Dual-Target Mechanism and Licensing Background
Ivonescimab is an investigational bispecific antibody engineered to simultaneously target two major pathways involved in tumor growth and immune evasion: programmed cell death protein 1 (PD-1) and vascular endothelial growth factor (VEGF). By blocking PD-1, the therapy aims to reactivate the immune system’s T-cells against cancer cells, while inhibiting VEGF targets the formation of new blood vessels that tumors require to grow and spread.
Summit Therapeutics acquired the rights to develop and commercialize ivonescimab in the United States, Canada, Europe, and Japan through a major licensing agreement with Chinese biopharmaceutical company Akeso in late 2022. The deal was valued at up to $5 billion, while Akeso retained rights to the drug in China and other regional markets.
The dual-target approach generated substantial interest across the oncology sector, as researchers hypothesized that combining immune checkpoint blockade with anti-angiogenic activity in a single molecule could offer improved efficacy compared to existing monotherapies or combination regimens.
Company Response and Future Outlook
Responding to the regulatory decision, Summit Therapeutics expressed ongoing commitment to the therapeutic candidate despite the immediate delay in reaching the U.S. market.
“We are disappointed for patients and their families awaiting additional treatment options in this setting,” said Summit Co-CEO Robert Duggan in a statement. Duggan emphasized that Summit and Akeso continue to evaluate ivonescimab across multiple clinical trials, noting that five Phase III studies in the broader development program have generated positive data.
Summit did not immediately specify whether it plans to request a formal meeting with the FDA or resubmit its application after additional long-term overall survival data from ongoing studies mature. The company is continuing to advance other cohorts within its lung cancer clinical program, including trials in squamous and non-squamous non-small cell lung cancer, which are expected to yield additional data readouts in late 2026 and early 2027.
